Imaging and cancer: A review

被引：547

作者：

Fass, Leonard ^{[1
,2
]}

机构：

[1] GE Healthcare, Slough SL1 4ER, Berks, England

[2] Univ London Imperial Coll Sci Technol & Med, Dept Bioengn, London, England

来源：

MOLECULAR ONCOLOGY | 2008年 / 2卷 / 02期

关键词：

Imaging; Cancer; Diagnosis; Staging; Therapy; Tracers; Contrast;

D O I：

10.1016/j.molonc.2008.04.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple biomedical imaging techniques are used in all phases of cancer management. Imaging forms an essential part of cancer clinical protocols and is able to furnish morphological, structural, metabolic and functional information. Integration with other diagnostic tools such as in vitro tissue and fluids analysis assists in clinical decision-making. Hybrid imaging techniques are able to supply complementary information for improved staging and therapy planning. Image guided and targeted minimally invasive therapy has the promise to improve outcome and reduce collateral effects. Early detection of cancer through screening based on imaging is probably the major contributor to a reduction in mortality for certain cancers. Targeted imaging of receptors, gene therapy expression and cancer stem cells are research activities that will translate into clinical use in the next decade. Technological developments will increase imaging speed to match that of physiological processes. Targeted imaging and therapeutic agents will be developed in tandem through close collaboration between academia and biotechnology, information technology and pharmaceutical industries. (C) 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved

引用

页码：115 / 152

页数：38

共 439 条

[1] Skin cancer identification using multifrequency electrical impedance -: A potential screening tool [J].

Åberg, P ;

Nicander, I ;

Hansson, J ;

Geladi, P ;

Holmgren, U ;

Ollmar, S .

IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, 2004, 51 (12) :2097-2102

[2]

Aboagye EO, 1999, CANCER RES, V59, P80

[3]

Aboagye EO, 1998, CANCER RES, V58, P1063

[4] Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors [J].

Abourbeh, Galith ;

Dissoki, Samar ;

Jacobson, Orit ;

Litchi, Amir ;

Ben Daniel, Revital ;

Laki, Desirediu ;

Levitzki, Alexander ;

Mishani, Eyal .

NUCLEAR MEDICINE AND BIOLOGY, 2007, 34 (01) :55-70

[5]

ALBERTONI P, 2003, BRIT J CANCER, V88, P996

[6]

*AM COLL RAD, 2004, BREAST IM REP DAT SY

[7] Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate [J].

Anderson, HL ;

Yap, JT ;

Miller, MP ;

Robbins, A ;

Jones, T ;

Price, PM .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2823-2830

[8] Ultrasound enhancement of cationic lipid-mediated gene transfer to primary tumors following systemic administration [J].

Anwer, K ;

Kao, G ;

Proctor, B ;

Anscombe, I ;

Florack, V ;

Earls, R ;

Wilson, E ;

McCreery, T ;

Unger, E ;

Rolland, A ;

Sullivan, SM .

GENE THERAPY, 2000, 7 (21) :1833-1839

[9] Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR [J].

Ardenkjaer-Larsen, JH ;

Fridlund, B ;

Gram, A ;

Hansson, G ;

Hansson, L ;

Lerche, MH ;

Servin, R ;

Thaning, M ;

Golman, K .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (18) :10158-10163

[10] MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles [J].

Artemov, D ;

Mori, N ;

Okollie, B ;

Bhujwalla, ZM .

MAGNETIC RESONANCE IN MEDICINE, 2003, 49 (03) :403-408

← 1 2 3 4 5 6 7 8 9 10 →